Cytori Therapeutics Inc Stock Deutsche Boerse AG
Equities
US23283K1051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 5.07M 4.65M | Sales 2025 * | 2.87M 2.63M | Capitalization | 10.38M 9.52M |
---|---|---|---|---|---|
Net income 2024 * | -15M -13.75M | Net income 2025 * | -29M -26.59M | EV / Sales 2024 * | 2.05 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.62 x |
P/E ratio 2024 * |
-0.87
x | P/E ratio 2025 * |
-0.79
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.82% |
Latest transcript on Cytori Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 62 | 02-09-30 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 20-02-05 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 62 | 02-09-30 |
Richard Hawkins
CHM | Chairman | 74 | 07-11-30 |
Robert Lenk
BRD | Director/Board Member | 76 | 20-02-29 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |